Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.1 Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality.2-5 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Parent Training in Behavior Management (PTBM) and...
- Clesrovimab (Enflonsia) for Prevention of Severe RSV Infection in Infants
- Mepolizumab (Nucala) for COPD
- Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
- In Brief: A New Donanemab (Kisunla) Dosing Regimen for Alzheimer's Disease
- In Brief: Pruritus Following Antihistamine Discontinuation
- In Brief: New Warning for Extended-Release Stimulants for ADHD
- In Brief: Hyperthermia with Scopolamine Patches
- Linvoseltamab (Lynozyfic) for Multiple Myeloma (online only)
RELEASE
On July 10, 2025 Pfizer issued a voluntary recall of certain lots of long-acting intramuscular (IM) benzathine penicillin G (Bicillin L-A) due to particulates identified during visual inspection.1 The CDC has issued a "Dear Colleague Letter" to alert healthcare providers about the recall and provide advice on how to manage the potentially limited supply of the drug for treatment of syphilis, which has been increasing in the US.2 Benzathine penicillin G is also used for treatment of group A streptococcal pharyngitis and prophylaxis of rheumatic fever.
In response to a previous shortage of Bicillin L-A in 2023, the FDA approved temporary importation of two equivalent IM penicillin formulations, Extencilline (benzathine benzylpenicillin) and Lentocilin S (benzathine benzylpenicillin tetrahydrate), both of which remain available (see Table 1).
SYPHILIS — IM …